Impact of preterm PROM and its complications on long-term infant outcomes

Clinical Obstetrics and Gynecology

Volumn 54, Issue 2, 2011, Pages 358-369

  Clark, Erin A S ^a   Varner, Michael ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Cerebral palsy; neurodevelopmental delay; preterm birth; preterm premature rupture of membranes (PPROM)

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6; LYMPHOTOXIN; MAGNESIUM SULFATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

AMNIONITIS; ANTIBIOTIC THERAPY; ARTICLE; BRAIN HEMORRHAGE; BRAIN PROTECTION; CHORIOAMNIONITIS; CHRONIC LUNG DISEASE; CONSERVATIVE TREATMENT; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; DELIVERY; DEVELOPMENTAL DISORDER; DRUG EFFICACY; FETAL INFLAMMATORY RESPONSE SYNDROME; FETUS DISEASE; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GESTATIONAL AGE; HUMAN; INFLAMMATION; LEUKOCYTOSIS; METRITIS; MOTOR DYSFUNCTION; NECROTIZING ENTEROCOLITIS; NEUROLOGIC DISEASE; NEWBORN INFECTION; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; RESPIRATORY DISTRESS SYNDROME; RISK BENEFIT ANALYSIS;

ADRENAL CORTEX HORMONES; CYTOKINES; FEMALE; FETAL MEMBRANES, PREMATURE RUPTURE; GENETIC PREDISPOSITION TO DISEASE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFLAMMATION; MAGNESIUM SULFATE; NERVOUS SYSTEM DISEASES; PREGNANCY; PREMATURE BIRTH; PROGNOSIS; TIME FACTORS; TOCOLYTIC AGENTS;

EID: 79955554661     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e318217ee18     Document Type: Article

References (40)

1. Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2005. Natl Vital Stat Rep. 2007;56:1-103.
2. ACOG Practice Bulletin No 80: Premature rupture of membranes. Clinical management guidelines for obstetriciangynecologists. Obstet Gynecol. 2007;109: 1007-1019.
3. Nelson KB. Causative factors in cerebral palsy. Clin Obstet Gynecol. 2008;51: 749-762.
4. Manuck TA, Eller AG, Esplin MS, et al. Outcomes of expectantly managed preterm premature rupture of membranes occurring before 24 weeks of gestation. Obstet Gynecol. 2009;114:29-37.
5. Kenyon SL, Taylor DJ, Tarnow-Mordi W. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. ORACLE Collaborative Group. Lancet. 2001;357:979-988. (Pubitemid 32285389)
6. Mercer BM, Miodovnik M, Thurnau GR, et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes: a randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA. 1997;278: 989-995. (Pubitemid 27430195)
7. Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev. 2010;8:CD001058.
8. Kenyon S, Pike K, Jones DR, et al. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. Lancet. 2008; 372:1319-1327.
9. Bhutta AT, Cleves MA, Casey PH, et al. Cognitive and behavioral outcomes of school-aged children who were born preterm: a meta-analysis. JAMA. 2002; 288:728-737. (Pubitemid 34848226)
10. Leviton A, Paneth N, Reuss ML, et al. Maternal infection, fetal inflammatory response, and brain damage in very low birth weight infants: Developmental Epidemiology Network Investigators. Pediatr Res. 1999;46:566-575. (Pubitemid 29496486)
11. Romero R, Gomez R, Ghezzi F, et al. A fetal systemic inflammatory response is followed by the spontaneous onset of preterm parturition. Am J Obstet Gynecol. 1998;179:186-193. (Pubitemid 28394494)
12. Yoon BH, Jun JK, Romero R, et al. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol. 1997;177: 19-26. (Pubitemid 27327305)
13. Ehrenberg HM, Mercer BM. Antibiotics and the management of preterm premature rupture of the fetal membranes. Clin Perinatol. 2001;28:807-818. (Pubitemid 33096843)
14. YoonBH, Romero R, Park JS, et al. Fetal exposure to an intra-amniotic inflammation and the development of cerebral palsy at the age of three years. Am J Obstet Gynecol. 2000;182:675-681. (Pubitemid 30207333)
15. Yoon BH, Romero R, Kim KS, et al. A systemic fetal inflammatory response and the development of bronchopulmonary dysplasia. Am J Obstet Gynecol. 1999; 181:773-779. (Pubitemid 29503589)
16. Spinillo A, Capuzzo E, Stronati M, et al. Effect of preterm premature rupture of membranes on neurodevelopmental outcome: follow up at two years of age. Br J Obstet Gynaecol. 1995;102:882-887.
17. Leviton A, Paneth N. White matter damage in preterm newborns-an epidemiologic perspective. Early Hum Dev. 1990;24:1-22. (Pubitemid 20344890)
18. Pasquier JC, Picaud JC, Rabilloud M, et al. Maternal leukocytosis after preterm premature rupture of membranes and infant neurodevelopmental outcome: a prospective, population-based study [Decrire L'ouverture des Membranes Inopinee le Nouveau-ne et l'Organisation des Soins (DOMINOS) Study]. J Obstet Gynaecol Can. 2007;29:20-26.
19. Buchanan SL, Crowther CA, Levett KM, et al. Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome. Cochrane Database Syst Rev. 2010;3:CD004735.
20. Mingione MJ, Pressman EK, Woods JR. Prevention of PPROM: current and future strategies. J Matern Fetal Neonatal Med. 2006;19:783-789. (Pubitemid 46033111)
21. Clark EA, Mele L, Wapner RJ, et al. Association of fetal inflammation and coagulation pathway gene polymorphisms with neurodevelopmental delay at age 2 years. Am J Obstet Gynecol. 2010; 203:83e1-83e10.
22. Gibson CS, Maclennan AH, Dekker GA, et al. Candidate genes and cerebral palsy: a population-based study. Pediatrics. 2008;122:1079-1085.
23. Nelson KB, Dambrosia JM, Iovannisci DM, et al. Genetic polymorphisms and cerebral palsy in very preterm infants. Pediatr Res. 2005;57:494-499. (Pubitemid 40389336)
24. Gibson CS, MacLennan AH, Goldwater PN, et al. The association between inherited cytokine polymorphisms and cerebral palsy. Am J Obstet Gynecol. 2006;194:674e1-674e11.
25. Harding D, Brull D, Humphries SE, et al. Variation in the interleukin-6 gene is associated with impaired cognitive development in children born prematurely: a preliminary study. Pediatr Res. 2005;58: 117-120. (Pubitemid 40967440)
26. Harding DR, Dhamrait S, Whitelaw A, et al. Does interleukin-6 genotype influence cerebral injury or developmental progress after preterm birth? Pediatrics. 2004;114:941-947. (Pubitemid 41529756)
27. Gibson CS, MacLennan AH, Goldwater PN, et al. Mannose-binding lectin haplotypesmay be associated with cerebral palsy only after perinatal viral exposure. Am J Obstet Gynecol. 2008;198:509e1-509e8.
28. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006;3: CD004454.
29. Harding JE, Pang J, Knight DB, et al. Do antenatal corticosteroids help in the setting of preterm rupture of membranes? Am J Obstet Gynecol. 2001;184:131-139. (Pubitemid 32141655)
30. Garite TJ, Kurtzman J, Maurel K, et al. Impact of a "rescue course" of antenatal corticosteroids: a multicenter randomized placebo-controlled trial. Am J Obstet Gynecol. 2009;200:248e1-248e9.
31. Wapner RJ, Sorokin Y, Thom EA, et al. Single versus weekly courses of antenatal corticosteroids: evaluation of safety and efficacy. Am J Obstet Gynecol. 2006;195: 633-642. (Pubitemid 44292122)
32. Crowther CA, Haslam RR, Hiller JE, et al. Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. Lancet. 2006;367:1913-1919. (Pubitemid 43831995)
33. Crowther CA, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. Cochrane Database Syst Rev. 2007;3:CD003935.
34. Murphy KE, Hannah ME, Willan AR, et al. Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial. Lancet. 2008;372:2143-2151.
35. Wapner RJ, Sorokin Y, Mele L, et al. Long-term outcomes after repeat doses of antenatal corticosteroids. N Engl J Med. 2007;357:1190-1198. (Pubitemid 47443178)
36. Crowther CA, Doyle LW, Haslam RR, et al. Outcomes at 2 years of age after repeat doses of antenatal corticosteroids. NEngl J Med. 2007;357:1179-1189. (Pubitemid 47443177)
37. Rouse DJ, Hirtz DG, Thom E, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med. 2008;359: 895-905.
38. Crowther CA, Hiller JE, Doyle LW, et al. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA. 2003;290:2669-2676. (Pubitemid 37475594)
39. Marret S, Marpeau L, Benichou J. Benefit of magnesium sulfate given before very preterm birth to protect infant brain. Pediatrics. 2008;121:225-226.
40. Costantine MM, Weiner SJ. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis. Obstet Gynecol. 2009;114:354-364.